| Name | Title | Contact Details |
|---|
Sengenics is a functional proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics. The key application of KREX™ is the discovery of autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies.
Obatala Sciences offers contract research services and research products to laboratories in industry and in academia. Our clients include US government entities, contract research organizations, non-profit organizations, and academic research laboratories. Our areas of expertise include obesity, diabetes, energy metabolism, musculoskeletal system biology, and wound healing. ObaCell, a unique fat tissue model, is a great tool for disease modeling and drug screening. Obatala Sciences can provide data in various areas depending on your interest including proteomics, genomics, functionality, and adipokine secretion. We also have the capability of forming white or brown fat tissue upon request.
Encorium Group, Inc is a Berwyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genprex (Nasdaq: GNPX) is a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes. Genprex`s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases.